Bantam Pharmaceutical

What Bantam Pharmaceutical does

Bantam Pharmaceutical is a privately held, clinical-stage biopharmaceutical company developing first-in-class, orally available small molecule therapeutics that target mitochondrial dynamics to restore apoptosis in cancer cells. The company's lead candidate, BTM-3566, works through a novel mechanism — hyperactivation of the mitochondrial protease OMA1, leading to cleavage of OPA1 and DELE1, activation of HRI kinase, and phosphorylation of eIF2α — thereby triggering the Integrated Stress Response and selective tumor cell death. The scientific foundation is based on IP acquired from Harvard at founding, and the company has built a SeMMiDs (Selective Modulators of Mitochondrial Dynamics) phenotypic discovery platform that has produced more than 600 compounds to date.

The lead program is focused on relapsed/refractory mature B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL), with initial Phase 1 activity also extending into aggressive solid tumors. BTM-3566 received FDA IND clearance and is being evaluated in a Phase 1 trial first activated at MD Anderson Cancer Center in February 2025, expanded into Canada in 2025, with the first patient dosed at Princess Margaret Cancer Centre in December 2025. Preclinical data includes complete tumor regression in 6 of 9 DLBCL patient-derived xenograft models and a 100% response rate in difficult-to-treat tumors; the company has also identified the FAM210B biomarker as a negative regulator enabling patient stratification.

The company operates a capital-efficient model with 1-10 employees, headquartered in Durham, North Carolina (Research Triangle Park). Total disclosed funding is approximately $25-30 million, primarily from a $25M seed round closed in September 2021 from co-founding and private investors. Bantam is pre-revenue with no commercial product, and its stated go-to-market is to seek partners and investors to drive clinical development from First-in-Humans to Proof of Concept, with future revenue anticipated through sales of approved oncology drugs (initially BTM-3566 in B-cell malignancies, expanding to solid tumors).

Name

Bantam Pharmaceutical

Legal name

Bantam Pharmaceutical, LLC

Website

https://bantampharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Bantam Pharmaceutical is a clinical-stage, privately held biopharmaceutical company developing BTM-3566, a first-in-class oral small molecule that targets mitochondrial dynamics to restore apoptosis in cancer cells, initially for relapsed/refractory B-cell lymphomas.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Oncology drug development
• Small molecule therapeutics
• Mitochondrial dynamics
• Hematologic cancer treatment
• Biopharmaceutical research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Drug Sales: As a pre-commercial biopharmaceutical company, Bantam Pharmaceutical plans to generate revenue through sales of approved drugs, initially focused on BTM-3566 for B-cell hematological malignancies with expansion into solid tumors.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Bantam Pharmaceutical is developing first-in-class orally available small molecule therapeutics (lead candidate BTM-3566) that selectively modulate mitochondrial dynamics in cancer cells to restore apoptosis. The company's pipeline targets relapsed/refractory B-cell lymphomas including DLBCL, MCL, and FL, with planned expansion into difficult-to-treat solid tumors. The SeMMiDs discovery platform identifies compounds that activate the mitochondrial protease OMA1, triggering the integrated stress response and tumor cell death independent of genetic mutation status.

Product overview

Bantam Pharmaceutical is developing novel, first-in-class small molecule oral therapeutics for difficult-to-treat hematological and solid tumors. The company's lead product is BTM-3566, an orally available small molecule targeting mitochondrial dynamics. The Discovery platform (SeMMiDs) uses phenotypic screening to identify compounds and biomarkers. BTM-3528 represents another pipeline candidate. The company integrates its scientific knowledge in mitochondrial cellular biology to drive clinical development focused initially on B-cell hematological malignancies with plans to expand into solid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• BTM-3566 Novel, orally available first-in-class small molecule compound that selectively modulates mitochondrial dynamics for treatment of hematologic and solid tumors. Initial clinical focus on relapsed/refractory mature B-cell lymphomas including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), with planned expansion into solid tumors. Works by inducing activation of OMA1, cleavage of OPA1 and DELE1, and triggering apoptosis through the integrated stress response.
• BTM-3528 Pipeline candidate small molecule from Bantam's novel class of compounds targeting the mitochondrial protease OMA1 for cancer treatment. Part of the SeMMiDs compound family alongside BTM-3566.

Quantifiable outcome

• Complete tumor regression in 6 of 9 DLBCL patient-derived xenograft (PDX) models with 100% response rate
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Princess Margaret Cancer CentrecoreOthers · 10 December 2025First patient treated in BTM-3566 Phase 1 clinical trial at The Princess Margaret Cancer Centre in Toronto, Canada. The trial is assessing safety, tolerability, and early efficacy signals in aggressive cancers including lymphomas and solid tumors.
• MD Anderson Cancer CentercoreOthers · 20 February 2025Activation of first Phase 1 clinical trial site at MD Anderson Cancer Center for BTM-3566 in relapsed/refractory mature B-cell lymphomas.
• Hannover Medical SchoolcoreStrategic or Co-development Partner · 6 September 2023Academic collaboration with Hannover Medical School for preclinical research on BTM-3566 mechanism of action. Dr. Adrian Schwarzer (MD, PhD) presented data at ASH and AACR meetings demonstrating therapeutic responses in DLBCL models.
• Molecular Cancer Therapeutics (AACR Journal)minorOthersPeer-reviewed publication in AACR journal on targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1, validating the scientific foundation of BTM-3566.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• ADC Therapeutics: Clinical-stage oncology company developing antibody-drug conjugates for relapsed/refractory B-cell lymphomas including DLBCL. Directly comparable to Bantam as both are clinical-stage hematologic oncology companies targeting similar patient populations with novel modalities.
• Verastem Oncology: Oncology company with a focus on B-cell malignancies and resistance pathways. Directly comparable as a clinical-stage biotech developing therapeutics for B-cell lymphomas with novel mechanisms of action.
• MEI Pharma: Clinical-stage oncology company developing small molecule therapies for B-cell malignancies including DLBCL. Comparable as a small-cap clinical biotech focused on hematologic cancer therapeutics.

Emerging players

• eFFECTOR Therapeutics: Was developing small molecules targeting the integrated stress response and translation initiation pathways in cancer. Comparable in mechanistic approach to Bantam's OMA1/ISR-targeting strategy, though focused on a different node in the same pathway.
• Raze Therapeutics: Was an early-stage oncology company developing small molecules targeting mitochondrial cancer metabolism (MTHFD2). Conceptually comparable to Bantam's mitochondrial dynamics approach in targeting cancer cell metabolism for therapeutic benefit.
• Mereo BioPharma: Clinical-stage biopharmaceutical company developing therapeutics for oncology and rare diseases. Comparable as a small-mid cap clinical biotech with oncology programs targeting difficult-to-treat patient populations.

Broad incumbents

• Bristol-Myers Squibb: Large oncology company with approved CAR-T therapy (lisocabtagene maraleucel) for relapsed/refractory DLBCL. Relevant as a major competitor in the DLBCL space Bantam is targeting and as a potential acquirer of clinical-stage assets.
• Gilead Sciences (Kite Pharma): Owns Kite Pharma, with an approved CAR-T therapy (axicabtagene ciloleucel) for relapsed/refractory DLBCL. A leading incumbent in the DLBCL treatment landscape and a likely strategic acquirer of novel B-cell lymphoma therapeutics.
• Roche: Has polatuzumab vedotin (Polivy) approved in DLBCL and a broad oncology pipeline. A relevant incumbent competitor and potential partner for novel mechanism B-cell lymphoma therapeutics.
• Incyte Corporation: Mid-cap oncology company with approved therapies for hematologic malignancies and a pipeline that includes DLBCL programs. A relevant incumbent for partnership or M&A consideration in the B-cell lymphoma space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bantam-pharmaceutical-llc/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bantam Pharmaceutical